Will Maja Salvador switch network to TV 5?


Maja Salvador’s career rose with ABS-CBN when she started playing a minor role for ‘It Might Be You’ in 2003. Her talent shone through which opened a lot of doors for her career. Now she’s starred in more films and teleseryes, including music albums.

However, Maja posted on her social media, hinting at her probable plans for leaving the network. She started her message by saying thank you to ABS-CBN and to all the people who supported her.

“Ako po ay taos pusong nagpapasalamat sa mga taong walang sawang sumusuporta sa akin at sa ABS-CBN.”

She also revealed that she will be following Mr. M or Johnny Manahan, Star Magic’s former head. She tells her fans not to be surprised as she will start working in a different broadcast network.

She has not revealed which network she will be going to but Mr. Manahan has been reported to be producing a new noontime show for TV5, Laugh out Loud. It will be part of the blocktime deal with Brightlight productions. The show as reported to be featuring other former kapamilya stars like Billy Crawford, Alex Gonzaga, K Brosas and Wacky Kiray.

She appeals to her fans’ continued support despite her decision, saying that it was her passion to give entertainment and happiness no matter which way or platform.

“Mga kapamilya, sasamahan ko po muna ang aking tatay na si Mr. M kaya sana wag po kayo magulat kung makikita niyo akong lumabas sa ibang network at patuloy makapagbigay ligaya sa inyo kahit sa anong paraang at plataporma.”

Brightlight Productions will be operating amongst other networks to secure block time slots for their programs featuring kapamilya stars.

Maja Salvador was notably known for her role in the television series, “Wildflower” as Lily Cruz / Ivy Aguas. Her impeccable acting skills were shown and visibly admired by viewers and fans alike.

Written by admin


Leave a Reply

Your email address will not be published. Required fields are marked *



Christine Reyes is back to GMA-7 after 12 years

Looking up for the vaccine authority was requested by Pfizer until November